DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06820476

CompletedPhase 1

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing

Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Oral Doses of NNC0487-0111 in Chinese Participants With Overweight or Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Amycretin / zenagamtide

Oral · GLP-1 / amylin

Listed sites

2

Recruiting sites

—

Enrollment

29

actual

Study population

Obesity / overweight

Key I/E criteria

•BMI 24-34.9•Male

Primary endpoint

•Treatment-emergent AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06820476
Org study IDNN9487-7573
Secondary IDU1111-1289-3164World Health Organization (WHO)

Timeline

Milestones

Study start2025-02-09actual
Study first posted2025-02-11actual
Primary completion2025-05-14actual
Study completion2025-05-14actual
Last update posted2025-08-20actual

Assets

Investigational agents

Amycretin / zenagamtide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age55 Years
SexMale
Healthy volunteersNot accepted

Inclusion criteria

•Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
•Male Chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent.
•Body mass index (BMI) between 24.0 and 34.9 kilogram per square meter (kg/m^2)(both inclusive), with a body weight greater than or equal to (>=) 65.0 kilogram (kg), at screening.
•Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

•Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
•Glycated haemoglobin (HbA1c) greater than or equal to (>=) 6.5 percent (%) (48 millimoles per mole [mmol/mol]) at screening
•Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
•Vitamin D (25-hydroxycholecalciferol) less than (<) 12 Nanograms per millilitre (ng/mL) (30 nanometer[nM]) at screening
•Parathyroid hormone (PTH) outside normal range at screening
•Total calcium outside normal range at screening
•Amylase greater than or equal to (>=) 2 times upper limit of normal at screening
•Lipase greater than or equal to (>=) 2 times upper limit of normal at screening
•Calcitonin greater than or equal to (>=) 50 picograms per milliliter (pg/mL) at screening

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
4
Weight & body composition
1
Glycemic / diabetes
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change in bodyweight

Time frame:From baseline Day 1 to Day 11

Body weight, % change

percent change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in fasting plasma glucose

Time frame:From baseline Day 1 to Day 11

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Safety / tolerability / PK

4 endpoints
Primary/protocol endpoint

Number of treatment emergent adverse events (TEAEs)

Time frame:From first NNC0487-0111 administration (Day 1) to completion of the end-of-study visit (Day 31)

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

AUC0-24h,MD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to 24 hours after last multiple dose

Time frame:From pre-dose on Day 10 until Day 11

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Cmax,MD; the maximum plasma concentration of NNC0487-0111 after last multiple dose

Time frame:From pre-dose on Day 10 to completion of the end-of-study visit (Day 31)

Cmax

concentration, descriptive

Secondary/protocol endpoint

tmax,MD; the time of maximum plasma concentration of NNC0487-0111 after last multiple dose

Time frame:From pre-dose on Day 10 to completion of the end-of-study visit (Day 31)

Tmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.